P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.

Abstract

The mTOR pathway is often upregulated in cancer and thus intensively pursued as a target to design novel anticancer therapies. Approved and emerging drugs targeting the mTOR pathway have positively affected the clinical landscape. Recently, activin receptor-like kinase 1 (ALK1), belonging to the TGFβ receptor family, has been reported as an emerging target… (More)
DOI: 10.1158/1535-7163.MCT-14-0486

Topics

6 Figures and Tables

Statistics

02040201520162017
Citations per Year

Citation Velocity: 7

Averaging 7 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{JalotaBadhwar2015P7170AN, title={P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.}, author={Archana Jalota-Badhwar and Dimple R. Bhatia and Srinivas Reddy Boreddy and Asavari A Joshi and Magesh Venkatraman and Nikesh K Desai and Sarika K. Chaudhari and Julie Bose and Lakshmi S. Kolla and Vijaykumar B Deore and Nilambari Yewalkar and Sanjay Kumar and Rajiv Kumar Sharma and Anagha A. Damre and Avinash More and Somesh Sharma and Veena R. Agarwal}, journal={Molecular cancer therapeutics}, year={2015}, volume={14 5}, pages={1095-106} }